Advisors Asset Management Inc. Acquires 1,145 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Advisors Asset Management Inc. lifted its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 4.3% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 27,612 shares of the pharmaceutical company's stock after buying an additional 1,145 shares during the quarter. Advisors Asset Management Inc.'s holdings in Vertex Pharmaceuticals were worth $11,119,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in VRTX. Truvestments Capital LLC grew its position in Vertex Pharmaceuticals by 30.3% during the 4th quarter. Truvestments Capital LLC now owns 99 shares of the pharmaceutical company's stock worth $40,000 after acquiring an additional 23 shares during the last quarter. Dunhill Financial LLC lifted its holdings in Vertex Pharmaceuticals by 70.6% in the 3rd quarter. Dunhill Financial LLC now owns 58 shares of the pharmaceutical company's stock worth $27,000 after buying an additional 24 shares during the period. Simon Quick Advisors LLC lifted its holdings in Vertex Pharmaceuticals by 1.1% in the 4th quarter. Simon Quick Advisors LLC now owns 2,236 shares of the pharmaceutical company's stock worth $900,000 after buying an additional 24 shares during the period. Spinnaker Trust lifted its stake in shares of Vertex Pharmaceuticals by 2.1% in the 4th quarter. Spinnaker Trust now owns 1,235 shares of the pharmaceutical company's stock valued at $497,000 after purchasing an additional 25 shares during the period. Finally, Strategic Advisors LLC lifted its stake in shares of Vertex Pharmaceuticals by 0.6% in the 4th quarter. Strategic Advisors LLC now owns 4,486 shares of the pharmaceutical company's stock valued at $1,807,000 after purchasing an additional 25 shares during the period. 90.96% of the stock is owned by institutional investors.

Remove Ads

Insider Activity

In other Vertex Pharmaceuticals news, EVP David Altshuler sold 3,231 shares of the business's stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $500.00, for a total transaction of $1,615,500.00. Following the completion of the transaction, the executive vice president now owns 26,512 shares of the company's stock, valued at approximately $13,256,000. The trade was a 10.86 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Ourania Tatsis sold 244 shares of the firm's stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $455.06, for a total transaction of $111,034.64. Following the completion of the transaction, the executive vice president now owns 67,695 shares of the company's stock, valued at approximately $30,805,286.70. This trade represents a 0.36 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 4,315 shares of company stock valued at $2,121,012. 0.20% of the stock is currently owned by insiders.

Vertex Pharmaceuticals Trading Down 1.4 %

Shares of VRTX stock traded down $6.98 during trading hours on Friday, reaching $503.20. 2,280,400 shares of the stock traded hands, compared to its average volume of 1,219,471. Vertex Pharmaceuticals Incorporated has a 1-year low of $377.85 and a 1-year high of $519.88. The business has a fifty day moving average price of $467.89 and a 200 day moving average price of $462.69. The company has a quick ratio of 2.35, a current ratio of 2.69 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $129.22 billion, a PE ratio of -228.73, a PEG ratio of 2.11 and a beta of 0.41.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last issued its quarterly earnings results on Monday, February 10th. The pharmaceutical company reported $3.54 earnings per share for the quarter, missing analysts' consensus estimates of $3.99 by ($0.45). Vertex Pharmaceuticals had a negative net margin of 4.86% and a negative return on equity of 2.02%. On average, equities research analysts forecast that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts have commented on the company. Canaccord Genuity Group raised Vertex Pharmaceuticals from a "sell" rating to a "hold" rating and lifted their target price for the stock from $408.00 to $424.00 in a report on Tuesday, February 11th. HC Wainwright reiterated a "buy" rating and set a $550.00 target price on shares of Vertex Pharmaceuticals in a research report on Tuesday, February 11th. JPMorgan Chase & Co. lowered their price objective on Vertex Pharmaceuticals from $503.00 to $500.00 and set an "overweight" rating on the stock in a research report on Monday, December 23rd. Bank of America lowered their price objective on Vertex Pharmaceuticals from $545.00 to $522.00 and set a "buy" rating on the stock in a research report on Thursday, December 19th. Finally, Needham & Company LLC reiterated a "hold" rating on shares of Vertex Pharmaceuticals in a research report on Tuesday, February 11th. Ten analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $506.70.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.